The U.S. FDA has granted Fast Track designation to INX-315, a novel CDK2 inhibitor, for treating CCNE1-amplified platinum-resistant/refractory ovarian cancer, potentially expediting its development and review process.
A groundbreaking study published in Nature Communications identifies biomarkers for response to INX-315, a selective CDK2 inhibitor, demonstrating potential effectiveness against various cancer types.